News
INVA
18.49
-2.84%
-0.54
Weekly Report: what happened at INVA last week (1109-1113)?
Weekly Report · 23h ago
Quarterly Loss Could Be A Game Changer For Innoviva (INVA)
Simply Wall St · 1d ago
Innoviva (INVA) And The Question Hanging Over Its Latest Update
Simply Wall St · 3d ago
H.C. Wainwright Keeps Their Buy Rating on Innoviva (INVA)
TipRanks · 3d ago
Impressive Earnings May Not Tell The Whole Story For Innoviva (NASDAQ:INVA)
Simply Wall St · 5d ago
INVA or MRK: Which Is the Better Value Stock Right Now?
NASDAQ · 11/09 15:40
Weekly Report: what happened at INVA last week (1102-1106)?
Weekly Report · 11/09 10:17
Innoviva (INVA) Stock Could Be Undervalued On Third Quarter Results
Simply Wall St · 11/06 04:56
Innoviva Price Target Cut to $34.00/Share From $35.00 by Oppenheimer
Dow Jones · 11/05 17:54
Innoviva Is Maintained at Outperform by Oppenheimer
Dow Jones · 11/05 17:54
Oppenheimer Maintains Outperform on Innoviva, Lowers Price Target to $34
Benzinga · 11/05 17:44
Innoviva price target lowered to $34 from $35 at Oppenheimer
TipRanks · 11/05 13:03
Innoviva (INVA) Could Be 39% Undervalued Following Third Quarter Loss
Simply Wall St · 11/05 03:45
Innoviva GAAP EPS of -$1.03 misses by $1.37, revenue of $106.12M misses by $9.19M
Seeking Alpha · 11/04 22:13
Press Release: Innoviva Reports Third Quarter 2026 Financial Results; Highlights Recent Company Progress
Dow Jones · 11/04 21:05
Innoviva Reports Earnings After Diversifying Away From the Business That Still Defines It
Barchart · 11/03 16:15
Pfizer (PFE) Surpasses Q3 Earnings and Revenue Estimates
NASDAQ · 11/03 12:00
Weekly Report: what happened at INVA last week (1026-1030)?
Weekly Report · 11/02 10:17
AbbVie (ABBV) Tops Q3 Earnings and Revenue Estimates
NASDAQ · 10/30 11:55
Innoviva And Its Real Value
Seeking Alpha · 10/27 21:57
More
Webull provides a variety of real-time INVA stock news. You can receive the latest news about Innoviva through multiple platforms. This information may help you make smarter investment decisions.
About INVA
Innoviva, Inc. is a diversified holding company with a portfolio of royalties and other healthcare assets. Its royalty portfolio includes respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol, FF/VI) and ANORO ELLIPTA (umeclidinium bromide/vilanterol, UMEC/VI). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement, it is entitled to receive royalties from GSK on sales of RELVAR/BREO, ELLIPTA. Its products include GIAPREZA (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock, and XERAVA (eravacycline) approved for the treatment of complicated intra-abdominal infections in adults. The third product, XACDURO, is for the treatment of hospital-acquired and ventilator-associated pneumonias caused by Acinetobacter in adults. The development pipeline includes zoliflodacin, an investigational treatment for uncomplicated gonorrhea is in a Phase III clinical trial.